ArticleNPJ precision oncology2026
RAD18 facilitates cancer progression and immunosuppression via the AKT/mTOR/c-Myc axis: a multi-omics analysis.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
RAD18, a key E3 ubiquitin ligase implicated in DNA repair and genome stability, is tightly linked to cancer malignant progression, yet its pan-cancer prognostic and immunotherapeutic value remains poorly defined. Herein, we performed a comprehensive pan-cancer multi-omics analysis and validated the oncogenic mechanisms of RAD18 in liver hepatocellular carcinoma, pancreatic adenocarcinoma and triple-negative breast cancer via in vitro and in vivo assays. RAD18 was significantly overexpressed in 22 cancer types, associated with gene mutation, hypomethylation, poor prognosis and favorable diagnostic efficacy, serving as an independent poor prognostic factor for multiple cancers. Mechanistically, RAD18 promoted tumor proliferation, migration and immunosuppressive microenvironment remodeling by activating the AKT/mTOR/c-Myc axis and regulating TGF-β1/PD-L1 expression. Moreover, low RAD18 expression predicted a favorable response to immune checkpoint blockade therapy, while its high expression correlated with anti-PD-1 resistance in triple-negative breast cancer. Collectively, our findings identify RAD18 as a potential pan-cancer prognostic biomarker and immunotherapeutic target, with targeting RAD18 holding promise for reversing immunotherapy resistance in solid tumors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.